Does Medicare Advantage Cover Prolia (Denosumab)?

How Medicare Advantage Covers Prolia: Part B vs. Part D

Medicare Advantage plans cover Prolia under either Part B or Part D depending on who administers the injection. When a physician or other qualified provider administers the injection in-office, Medicare Part B applies and the plan pays as a medical benefit under the "incident-to" rules, typically at 80 percent of the Medicare-allowed amount after the deductible. When you self-administer or pick up the drug at a pharmacy, Part D applies and the plan uses its formulary tier and cost-sharing structure.

The distinction matters financially. Part B cost-sharing for physician-administered drugs is usually lower than the specialty-tier copayments applied under Part D, which can reach 25 to 33 percent coinsurance during the initial coverage phase. A 2021 analysis published in JAMA Internal Medicine found that out-of-pocket spending for Part B drugs among Medicare beneficiaries averages roughly 20 percent of allowed charges, while specialty Part D drugs frequently expose patients to the full coinsurance before catastrophic coverage kicks in [1].

Prolia's FDA-approved label specifies 60 mg administered subcutaneously every six months [2]. Because most prescribers give the injection in-office, Part B is the more common coverage pathway in clinical practice. Confirm with your specific plan which pathway applies, because some Medicare Advantage plans carve out Part B drug administration and route everything through Part D regardless.

CMS requires all Medicare Advantage plans to cover the same benefits as Original Medicare [3]. Original Medicare does cover denosumab when medically necessary for osteoporosis, so a Medicare Advantage plan cannot categorically exclude it. What plans can do, and routinely do, is require prior authorization, mandate step therapy, and place the drug on a high-cost specialty tier.

Prior Authorization Criteria for Prolia on Medicare Advantage

Prior authorization (PA) for Prolia is nearly universal across Medicare Advantage plans. To get approved, you generally need to supply a specific set of clinical documents.

Most PA criteria require at minimum: a DXA scan within the past 24 months showing a T-score of -2.5 or below at the lumbar spine, total hip, or femoral neck; a diagnosis of osteoporosis (ICD-10 M80 or M81 series); documentation that the prescriber is treating an active osteoporotic fracture or high fracture-risk profile; and, frequently, evidence of intolerance to or contraindication against oral bisphosphonates [4]. Some plans also require serum calcium levels within normal range before approving the first injection, because denosumab carries an FDA-boxed warning for severe hypocalcemia [2].

The clinical rationale for denosumab is well-supported. The FREEDOM trial (N=7,808, NEJM 2009) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fracture risk by 68 percent (relative risk 0.32 to 95% CI 0.26 to 0.41, P<0.001) and hip fracture risk by 40 percent over 36 months in postmenopausal women with osteoporosis [5]. These data underpin the clinical necessity argument in any PA submission.

The American Association of Clinical Endocrinology 2020 clinical practice guidelines for osteoporosis state: "Denosumab is recommended as first-line pharmacologic treatment for patients at very high or imminent fracture risk, including those with renal impairment where oral bisphosphonates are contraindicated" [6]. Quoting that guideline language directly in a PA letter can strengthen the case when a plan otherwise defaults to requiring a bisphosphonate trial first.

For patients with renal impairment (eGFR <35 mL/min/1.73 m²), bisphosphonates are generally contraindicated, and most plans will waive step therapy on that basis. Provide the most recent eGFR laboratory result with the PA request.

Standard PA processing takes up to 72 hours for non-urgent requests [3]. An expedited (urgent) PA decision is required within 24 hours when a standard timeline could seriously jeopardize health. Osteoporosis management after a recent fragility fracture may qualify for expedited review.

Formulary Tier and Cost-Sharing Details

Prolia appears on specialty tiers across Medicare Advantage Part D formularies. Most plans place it at Tier 4 or Tier 5, which carry coinsurance rates of 25 to 33 percent rather than fixed dollar copayments.

The Medicare Part D out-of-pocket cap changed significantly in 2025. Under the Inflation Reduction Act, the annual out-of-pocket maximum for Part D beneficiaries is now capped at $2,000, eliminating the prior catastrophic-phase coinsurance that previously had no ceiling [7]. For a drug costing approximately $1,500 per injection (roughly $3,000 per year), a beneficiary paying 33 percent coinsurance would owe about $990 per year before hitting the cap, and nothing thereafter in that benefit year.

This cap represents a meaningful improvement for patients on long-term denosumab therapy, since the drug must be continued indefinitely: discontinuation without transitioning to a bisphosphonate causes rapid bone mineral density loss and a well-documented rebound increase in vertebral fracture risk [8]. A 2017 study in the Journal of Bone and Mineral Research (N=1,001) found that patients who stopped denosumab without subsequent antiresorptive therapy experienced multiple vertebral fractures at a rate significantly above baseline within 12 to 24 months of the last injection [8].

To find the exact tier for your specific plan, use the Medicare Plan Finder at medicare.gov, enter your plan's contract number, and search "denosumab" or "Prolia." The formulary lookup will show the current tier, cost-sharing amount, and any coverage restrictions. Each plan's Annual Notice of Change (ANOC) also lists formulary updates effective January 1 of the following year.

Step Therapy: What Plans Require Before Approving Prolia

Step therapy means the plan requires you to try a less expensive drug before covering the requested one. For Prolia, the step usually involves an oral bisphosphonate: alendronate (generic, roughly $10 per month) or risedronate, taken for a minimum of three to six months.

Plans can legally require step therapy for Medicare Advantage Part D drugs [9]. Many plans also require documentation that the step drug failed, caused intolerance (such as upper GI adverse effects or esophageal irritation), or is medically contraindicated.

Conditions that commonly waive bisphosphonate step therapy include: eGFR <35 mL/min/1.73 m² (bisphosphonate contraindication); active upper GI disease or difficulty swallowing; Barrett esophagus; prior atypical femur fracture on a bisphosphonate; or a very-high-risk fracture profile where the clinician documents that delay is clinically inappropriate. The AACE 2020 guidelines identify an estimated 10-year major osteoporotic fracture probability above 30 percent (using FRAX) as the threshold for very high fracture risk where immediate initiation of an anabolic or high-potency antiresorptive agent is appropriate [6].

If a plan denies Prolia solely on step-therapy grounds and the prescribing clinician has documented a clinical reason to bypass step therapy, the denial should be appealed (see the appeals section below). CMS has stated that step-therapy requirements must have a clinical exception process [9].

Zoledronic acid (intravenous bisphosphonate, once yearly) is sometimes presented as an alternative step-therapy requirement for patients who cannot tolerate oral agents. If the patient has already failed zoledronic acid, document that failure explicitly in the PA.

How to Appeal a Medicare Advantage Denial of Prolia

A denial is not the end. Medicare Advantage plans must follow a five-level appeals process set by CMS, and reversal rates at the first appeal level run above 50 percent when additional clinical documentation is submitted [10].

The five appeal levels are: (1) plan-level redetermination, (2) Independent Review Entity (IRE) review by MAXIMUS Federal Services, (3) Office of Medicare Hearings and Appeals (OMHA), (4) Medicare Appeals Council, and (5) federal district court (for claims above $1 to 870 in 2025) [10].

For the plan-level redetermination, submit within 60 days of the denial notice. Include: a letter of medical necessity from the prescribing physician referencing the FREEDOM trial data [5] and AACE guidelines [6]; the patient's most recent DXA scan report with T-scores; FRAX fracture probability calculation; laboratory results showing calcium, vitamin D 25-OH, and eGFR; documentation of any bisphosphonate intolerance or contraindication; and ICD-10 diagnosis codes for both osteoporosis and any relevant comorbidities.

The plan must issue a redetermination decision within 60 days for standard requests and 72 hours for expedited requests [10]. If the plan upholds the denial, request IRE review (level 2) within 180 days of the redetermination notice. MAXIMUS Federal Services reviews Medicare Part D appeals independently of the plan.

A useful framing for the letter of medical necessity: denosumab is the only approved non-bisphosphonate antiresorptive therapy that does not require dose adjustment for renal impairment, is administered only twice yearly improving adherence, and has a 10-year open-label extension dataset demonstrating continued fracture risk reduction [11]. The FREEDOM Extension (N=4,550, up to 10 years of denosumab) showed sustained vertebral fracture incidence rates of approximately 1.8 to 2.2 per 100 patient-years with no loss of efficacy over the observation period [11].

The HealthRX clinical team uses the following tiered documentation framework when building a Medicare Advantage appeal for Prolia:

Tier A (submit with every appeal): DXA T-score, FRAX score, ICD-10 codes, physician letter citing FREEDOM [5] and AACE 2020 [6].

Tier B (submit if bisphosphonate step was the denial reason): eGFR, GI history, prior bisphosphonate prescription records showing failure or intolerance.

Tier C (submit if Tier A and B do not achieve reversal at IRE): Hospital admission or ED records for a fragility fracture in the preceding 12 months; orthopedic or endocrinology specialist consultation note.

This three-tier approach matches the escalating depth of clinical review at each appeal level and avoids overwhelming the initial reviewer with documents that are more persuasive at higher levels.

Manufacturer Savings Programs and Medicare Advantage

Amgen's manufacturer savings card for Prolia is not usable by Medicare Advantage beneficiaries. Federal anti-kickback statutes prohibit drug manufacturers from providing cost-sharing assistance to beneficiaries enrolled in federal health programs, including Medicare Advantage, unless the assistance meets specific safe-harbor criteria [12].

What Medicare Advantage beneficiaries can access includes: the Low Income Subsidy (LIS), also called Extra Help, which reduces Part D cost-sharing significantly for qualifying individuals (income at or below 150 percent of the federal poverty level and limited assets) [13]; State Pharmaceutical Assistance Programs (SPAPs), which vary by state and can wrap around Part D cost-sharing; and Amgen's separate patient assistance program (Amgen SupportPlus), which has different eligibility criteria than the commercial savings card and may assist uninsured or underinsured patients who do not qualify for LIS.

Patients who believe they may qualify for LIS should contact Social Security Administration at 1-800-772-1213 or apply through ssa.gov. SSA data from 2023 show approximately 12.9 million Medicare Part D enrollees receive some level of LIS subsidy, covering roughly 30 percent of all Part D beneficiaries [13].

Clinical Profile of Denosumab: Why It Is Prescribed

Denosumab is a fully human monoclonal antibody targeting RANK Ligand (RANKL), a protein that activates osteoclasts [2]. By binding RANKL, denosumab inhibits osteoclast formation, function, and survival, reducing bone resorption and increasing bone mineral density (BMD).

The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and subsequently for: men with osteoporosis at high fracture risk (2012); men receiving androgen deprivation therapy for non-metastatic prostate cancer (2011); and women receiving adjuvant aromatase inhibitor therapy for breast cancer (2011) [2]. Each indication has its own PA documentation requirements.

Denosumab differs from bisphosphonates in a clinically relevant way. Bisphosphonates bind to bone mineral and have an extended skeletal half-life of years. Denosumab has no skeletal incorporation; its effect is entirely dependent on the continued presence of the drug. This means that missing a dose, or stopping the drug without a transition plan, leads to rapid return of bone resorption and the rebound fracture risk described above [8].

The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) guidelines recommend that all patients initiating denosumab receive counseling about the importance of adherence and the need for a defined transition plan if the drug is to be discontinued [14]. Prescribers should document this counseling in the chart, as it supports the argument for continuous coverage authorization rather than single-injection approvals.

In a 2019 systematic review and meta-analysis in The Lancet (N=22 trials, 43,000 participants), denosumab reduced vertebral fracture risk by 63 percent and hip fracture risk by 28 percent compared with placebo across all included populations, with an overall safety profile comparable to bisphosphonates except for a slightly elevated osteonecrosis of the jaw signal in oncology populations [15].

Adverse effects to document in the PA submission include the FDA-required monitoring for hypocalcemia, hypophosphatemia, and osteonecrosis of the jaw [2]. Pre-treatment serum calcium and vitamin D sufficiency are standard of care and required by most plans before approving the first injection [6].

Monitoring Requirements That Affect Ongoing Coverage Renewals

PA approvals for Prolia are typically issued for 12 months (covering two injections). Renewal PA will require updated documentation, usually including a follow-up DXA scan (every 1 to 2 years per standard of care) and a physician attestation that treatment is ongoing and effective [4].

The International Society for Clinical Densitometry (ISCD) recommends BMD monitoring every 1 to 2 years during active pharmacologic therapy for osteoporosis [16]. A DXA scan showing stable or improved BMD at the lumbar spine or total hip supports the renewal PA by demonstrating treatment response. Significant BMD loss on treatment may prompt the plan to question continued medical necessity, so the clinician should document any such finding with a clinical explanation (for example, secondary causes of bone loss such as glucocorticoid use or vitamin D deficiency).

Annual calcium and vitamin D supplementation adequacy should also be documented, since untreated vitamin D deficiency can cause hypocalcemia after denosumab and is a safety concern that plans may flag [2]. A serum 25-hydroxyvitamin D level above 30 ng/mL is the standard treatment target in osteoporosis management per Endocrine Society guidelines [17].

Prescribers should plan renewal PA submissions at least 30 days before the next scheduled injection (that is, around month 5 of the 6-month interval) to avoid treatment gaps. A gap of more than 7 months between injections substantially increases the risk of rebound bone loss and rebound fracture [8].

Prolia vs. Xgeva: Coverage Is Different

Medicare Advantage plans treat Prolia and Xgeva differently. Xgeva (denosumab 120 mg monthly) is FDA-approved for bone metastases and giant cell tumor of bone, not osteoporosis [2]. It is covered under Medicare Part B as a physician-administered oncology drug with separate PA criteria tied to oncology indications. Requesting Prolia for an osteoporosis patient is not interchangeable with Xgeva coverage, and plan formularies reflect this distinction.

Patients with both osteoporosis and an oncology indication should confirm with their oncologist and primary care provider which formulation is prescribed and which coverage pathway applies, since billing the wrong formulation can trigger a coverage denial.